ProCE Banner Activity

Integrating New AML Drugs Into a Rapidly Changing Treatment Paradigm

Clinical Thought
Multiple novel agents have recently been approved for AML, dramatically affecting the treatment landscape. Read my commentary to see how these drugs have changed, and will continue to change, our clinical practices.

Released: March 22, 2019

Expiration: March 20, 2020

Share

Faculty

Farhad Ravandi

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Celgene

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals, Inc.

Faculty Disclosure

Primary Author

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Farhad Ravandi, MD, has disclosed that he has received consulting fees from AbbVie, Agios, Amgen, Astellas, Bristol-Myers Squibb, and MacroGenics and funds for research support from AbbVie, Amgen, Bristol-Myers Squibb, MacroGenics, and Xencor.